Article Text

other Versions

PDF
Case series
Critical assessment of complications associated with use of the Pipeline Embolization Device
  1. Min S Park1,
  2. Felipe C Albuquerque1,
  3. Michael Nanaszko1,
  4. Matthew R Sanborn1,
  5. Karam Moon1,
  6. Adib A Abla2,
  7. Cameron G McDougall1
  1. 1Department of Neurological Surgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
  2. 2Department of Neurological Surgery, University of California San Francisco Medical Center, San Francisco, California, USA
  1. Correspondence to
    Dr Felipe C Albuquerque, c/o Neuroscience Publications, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, 350 W. Thomas Road, Phoenix, AZ 85013, USA; Neuropub{at}dignityhealth.org

Abstract

Background The Pipeline Embolization Device (PED) has become an important tool in the treatment of complex cerebrovascular pathology since it was approved by the Food and Drug Administration in April 2011.

Objective To determine the overall complication rate (permanent and transient) associated with the use of this new device from a single institution.

Methods We retrospectively examined a prospectively maintained database of our patients treated with the PED since its availability to the current time. 126 patients (24 men, 102 women; age range 14–83 years, mean 59.8 years) were treated for a total of 137 intracranial aneurysms, one cervical internal carotid artery dissection, one cervical vertebral artery dissection, and one carotid-cavernous fistula with a total of 217 PEDs (1.72 PED/patient).

Results A total of 40 complications were experienced by 33 patients in our cohort. Four complications (4/126, 3.2%) in four patients were permanent, resulting in three deaths and one permanent disability. The other 36 complications (28.6%) occurred in 29 patients, all of whom went on to recover completely. The total complication rate associated with the use of the PED was 31.7% (40/126).

Conclusions Despite a low rate of permanent complications associated with the PED in this series, the total complication rate was high. This finding supports the conclusion that this device should be reserved for the most challenging aneurysms. Patients should be advised of this higher rate of transient periprocedural complications.

Trial registration number IRB#:14BN027 Q7.

  • Complication
  • Device

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.